Amendments

Please amend the above-identified application as follows:

In the Claims,

Please amend the following claims.

- 2. (Amended) An adenoviral vector as described in claim 1 or 15 wherein said deletion of said E1b region genes comprises p19, 55K, and pIX.
- 6. (Amended) An recombinant adenoviral vector as described in claim 1 or 15 wherein said heterologous gene encodes a protein selected from the group consisting of tumor necrosis factor alpha, interferon gamma, an interleukin, a cell suicide protein, cytosine deaminase, thymidine kinase and mip-3.
- 7. (Amended) Cells comprising said adenoviral vectors of claim 1 or 15.
- (Amended) A method for treating a mammal having a neoplastic condition in need of said treatment, comprising administering to said mammal a therapeutically effective dose of said adenoviral vectors of claims 1, 5, [or] 6 or
 15.

Please add the following claim.

--15. (New) A recombinant adenoviral vector comprising a deletion of E1b region gene(s), but retaining the E1b promoter, and substituting for said E1b region gene(s) a heterologous gene that is operable linked to said E1b promoter. --